Ccrn4l as a pre-dose marker for prediction of cisplatin-induced hepatotoxicity susceptibility

Da Bin Hwang, Dong Hoon Won, Yoo Sub Shin, Shin Young Kim, Byeong Cheol Kang, Kyung Min Lim, Jeong Hwan Che, Ki Taek Nam, Jun Won Yun

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Clinical cisplatin use is often limited by its drug-induced liver injury (DILI). Particularly, individual differences in susceptibility to DILI can cause life-threatening medical conditions. This study aimed to uncover the inherent genetic factors determining individual variations in hepatotoxicity susceptibility. Rats were subjected to liver biopsy and a 3-week postoperative recovery period before cisplatin administration. At 2 days post-treatment with cisplatin, the rats exhibited histopathological and serum biochemical alterations in the liver, and changes in hydrogen peroxide and cytochrome P450-2E1 levels. Based on these results of liver-related biochemical markers, 32 rats were grouped into the susceptible (top five) and resistant (bottom five) groups. Using RNA-sequencing, we compared gene expressions in the liver pre-biopsied from these two groups before cisplatin treatment and found 161 differently expressed genes between the Susceptible and Resistant groups. Among them, the clock-controlled Ccrn4l responsible for ‘rhythmic process’ was identified as a common gene downregulated inherently prior to drug exposure in both cisplatin- and acetaminophen-sensitive animals. Additionally, low Ccrn4l levels before cisplatin treatment in the Susceptible group were maintained even after treatment, with decreased antioxidants, increased nitration, and apoptosis. The relationship of Ccrn4l with catalase and mitochondrial RNAs in the liver was confirmed by correlation of their hepatic levels among individuals and similar patterns of circadian variation in their mRNA expression. Remarkably, Ccrn4l knockdown promoted cisplatin-induced mitochondrial dysfunction in WB-F344 cells with antioxidant catalase and apoptosis-related Bax changes. Inherent individual hepatic Ccrn4l level might be a novel factor affecting cisplatin-induced hepatotoxicity susceptibility, possibly through regulation of mitochondrial and antioxidant functions.

Original languageEnglish
Pages (from-to)128-139
Number of pages12
JournalFree Radical Biology and Medicine
Publication statusPublished - 2020 Feb 20

Bibliographical note

Funding Information:
The author would like to thank Dr. Xingen Lei (Cornell University, Ithaca, NY, USA) for critical review of the manuscript. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education ( 2017R1D1A1B03031604 ) and the Bio & Medical Technology Development Program of the NRF funded by the Korean government , MSIP ( NRF-2016M3A9D5A01952416 ). This work was supported by the Catholic University of Korea, Research Fund, 2019.

Publisher Copyright:
© 2020 Elsevier Inc.

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Physiology (medical)


Dive into the research topics of 'Ccrn4l as a pre-dose marker for prediction of cisplatin-induced hepatotoxicity susceptibility'. Together they form a unique fingerprint.

Cite this